
## Geetha P Bansal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11216121/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine, 2015, 33, 5064-5071.	3.8	75
2	Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. European Journal of Immunology, 1995, 25, 226-231.	2.9	30
3	Immunological Cross-Reactivity between Malaria Vaccine Target Antigen P48/45 in Plasmodium vivax and P. falciparum and Cross–Boosting of Immune Responses. PLoS ONE, 2016, 11, e0158212.	2.5	21
4	Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances. Current Opinion in Molecular Therapeutics, 2010, 12, 39-46.	2.8	19
5	Suppression of bacterial cell wall-induced polyarthritis by recombinant gamma interferon. Cytokine, 1991, 3, 98-106.	3.2	17
6	Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharmaceutical Research, 2015, 32, 3827-3836.	3.5	16
7	Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by <i>In Vivo</i> Electroporation in Preclinical Studies in Mice. Vaccine Journal, 2015, 22, 1013-1019.	3.1	15
8	Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine, 2017, 35, 264-272.	3.8	14
9	Functional Conservation of P48/45 Proteins in the Transmission Stages of <i>Plasmodium vivax</i> (Human Malaria Parasite) and <i>P</i> . <i>berghei</i> (Murine Malaria Parasite). MBio, 2018, 9, .	4.1	13
10	Antibodies elicited during natural infection in a predominantly Plasmodium falciparum transmission area cross-react with sexual stage-specific antigen in P. vivax. Acta Tropica, 2017, 170, 105-111.	2.0	12
11	Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe. Acta Tropica, 2016, 163, 103-108.	2.0	11
12	Insight into phagocytosis of mature sexual (gametocyte) stages of Plasmodium falciparum using a human monocyte cell line. Acta Tropica, 2016, 157, 96-101.	2.0	11
13	Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques. Vaccine, 2017, 35, 7049-7056.	3.8	8
14	Reduced immunogenicity of <i>Plasmodium falciparum</i> gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds – evaluating effect of interferonâ€ <i>γ</i> â€inducible lysosomal thiol reductase. Immunology, 2016, 148, 433-447.	4.4	7
15	Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes. Pharmaceutical Research, 2017, 34, 1796-1804.	3.5	6
16	Immune Responses in Malaria Transmission. Current Clinical Microbiology Reports, 2018, 5, 38-44.	3.4	4
17	The Right Stand by ASM regarding Journal Impact Factors. Infection and Immunity, 2016, 84, 3655-3655.	2.2	0